Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
Rising demands and advancements in eye care drive growth
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
The acquisition is for an enterprise value of Rs. 218 crores
Subscribe To Our Newsletter & Stay Updated
